Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Zacks Research

Delcath Systems (NASDAQ:DCTH) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Separately, Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Delcath Systems presently has an average rating of “Moderate Buy” and an average target price of $22.50.

Delcath Systems Price Performance

DCTH opened at $13.10 on Tuesday. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $13.74. The stock has a market capitalization of $452.21 million, a P/E ratio of 1,310.00 and a beta of 0.49. The business has a 50 day simple moving average of $11.57 and a 200-day simple moving average of $10.48.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07. The firm had revenue of $24.99 million for the quarter, compared to the consensus estimate of $23.51 million. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. Research analysts anticipate that Delcath Systems will post -0.88 EPS for the current year.

Hedge Funds Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC acquired a new position in shares of Delcath Systems during the third quarter worth $7,164,000. Marshall Wace LLP acquired a new stake in Delcath Systems during the 2nd quarter valued at $6,572,000. Divisadero Street Capital Management LP purchased a new stake in Delcath Systems during the 3rd quarter worth $5,119,000. Rosalind Advisors Inc. increased its stake in Delcath Systems by 13.8% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock worth $44,885,000 after buying an additional 400,000 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in Delcath Systems by 116.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock worth $5,936,000 after buying an additional 315,583 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.